Wintech Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 3.45 M
as on 17-07-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.59 Cr
as on 17-07-2024
- Revenue -5.84%
(FY 2023)
- Profit -20.29%
(FY 2023)
- Ebitda -2.13%
(FY 2023)
- Net Worth 3.22%
(FY 2023)
- Total Assets 0.23%
(FY 2023)
About Wintech Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.45 M.
The company currently has active open charges totaling ₹5.59 Cr.
Piyush Chhajed, Varsha Chhajed, and Ashok Chhajed serve as directors at the Company.
- CIN/LLPIN
U74999MH2018PLC306509
- Company No.
306509
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Mar 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Wintech Pharmaceuticals Limited offer?
Wintech Pharmaceuticals Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Osteoporosis Medications, Cardiovascular Drugs & Medication, Blood Pressure Medicine, Nutraceuticals & Dietary Supplements, Mineral Supplement, Common Disease Medicines, Antihistamines, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Wintech Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Piyush Chhajed  | Director | 15-Mar-2018 | Current |
| Varsha Chhajed | Director | 02-Jan-2021 | Current |
| Ashok Chhajed | Director | 20-Feb-2019 | Current |
Financial Performance of Wintech Pharmaceuticals.
Wintech Pharmaceuticals Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.84% decrease. The company also saw a substantial fall in profitability, with a 20.29% decrease in profit. The company's net worth moved up by a moderate rise of 3.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wintech Pharmaceuticals?
In 2023, Wintech Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 21 May 2021 | ₹5.59 Cr | Open |
How Many Employees Work at Wintech Pharmaceuticals?
Wintech Pharmaceuticals has a workforce of 64 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wintech Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wintech Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
